CA9 and colorectal cancer: Our earlier studies showed that SLC-0111, a novel CA IX inhibitor, is able to synergize with cytotoxic drugs such as Dacarbazine, Doxorubicine and 5-Fluorouracil in melanoma, breast and colorectal cancer cell lines, which express high levels of CA IX also in normoxia.26